News, Short Squeeze, Breakout and More Instantly...
COPENHAGEN, Denmark, Jan. 10, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates that address unmet medical needs, will provide an update on Vision 3x3 and the compa...
VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China PR Newswire SHANGHAI , Jan. 9, 2021 /PRNewswire/ -- VISEN Pharmaceuticals, a biotech comp...
– Advances Vision 3x3 to extend global clinical and commercial reach – COPENHAGEN, Denmark, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create...